论文部分内容阅读
曲美他嗪是一种通过优化心肌能量代谢的抗心肌缺血药物,常用来治疗稳定型心绞痛。近年来随着研究的深入,临床应用日益广泛,已经从单纯的抗心绞痛药物发展到几乎适合所有的冠心病患者。传统抗心肌缺血药物在冠心病合并糖尿病患者治疗中存在一定的局限性,曲美他嗪能够加强心肌葡萄糖的代谢作用,提高了缺血阈值,改善血管内皮功能,不影响血流动力学,患者耐受性好,可以弥补传统药物不足。
Trimetazidine is an anti-ischemic drug that is used to optimize myocardial energy metabolism and is commonly used to treat stable angina. In recent years, with the deepening of research, clinical application is increasingly widespread, has been developed from simple anti-anginal drugs to almost all patients with coronary heart disease. Traditional anti-ischemic drugs have some limitations in the treatment of patients with coronary heart disease and diabetes mellitus, trimetazidine can enhance myocardial glucose metabolism, improve the ischemic threshold, improve endothelial function, does not affect hemodynamics, Patients are well tolerated and can make up for the lack of traditional medicines.